MedPath

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Conditions
Pollen Allergy
Registration Number
NCT03727399
Lead Sponsor
Mabylon AG
Brief Summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
300
Inclusion Criteria
  • History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
  • Male or female patients older than 18 years
  • Written informed consent for providing blood and also to allow experimental manipulation
Exclusion Criteria
  • Age < 18 years
  • Any corticosteroids within the last three days
  • Oral corticosteroid therapy within the last ten days
  • Parenteral depot corticosteroids within the last three months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Antibody profilingOctober 2018 - September 2021

Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Immunologie Zentrum Zürich

🇨🇭

Zürich, Switzerland

Immunologie Zentrum Zürich
🇨🇭Zürich, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.